Tag: GlobeNewswire

Highlights Include Landmark Agreement with Nebius, Expansion of Power Portfolio, and Funding Strategy for CLT1

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) —  AIB Data Centers, Inc. (NYSE American: AIB) (“AIB” or the “Company”), a developer and operator of digital infrastructure focused on artificial intelligence and high-performance computing workloads, today issued a letter to shareholders from Chief Executive Officer Jerry Tang highlighting the Company’s significant recent progress and outlining its development and funding strategy for CLT1.

Recent developments highlighted in the letter include:

• Execution of a 12-year agreement with Nebius for 50 MW of critical IT capacity at AIB’s CLT1 data center campus, with two potential five-year renewal periods.
• Significant customer funding support for CLT1 development, including contractual customer prepayments expected to fund a meaningful portion of the initial development.
• A project-level financing strategy designed to complement customer funding with potential project-level debt and preferred equity.
• Commercial validation of AIB’s power-first development strategy, with the Nebius agreement demonstrating the Company’s ability to convert secured power capacity into long-term contracted data center capacity.
• Completion of a strategic Texas acquisition that increased AIB’s total contracted utility power capacity from 65 MW to approximately 120 MW
• Continued expansion of AIB’s development pipeline and power portfolio, positioning the Company to pursue additional AI and high-performance computing opportunities.

Based on AIB’s current development plan and anticipated sources of project financing, including customer prepayments and project-level financing, the Company does not currently anticipate requiring corporate-level common equity to fund the development of CLT1.

Letter from the Chief Executive Officer

Dear Fellow Shareholders,

The past 30 days have been among the most consequential periods in AIB Data Centers’ development.

During this period, we have taken significant steps toward transforming AIB from a company assembling a portfolio of strategically located, power-rich data center sites into an operating platform with contracted capacity from a leading AI infrastructure customer.

Most importantly, we announced our agreement with Nebius for 50 MW of critical IT capacity at our CLT1 data center campus. The agreement has an initial term of 12 years, with two potential five-year renewal periods. We believe this represents an important validation not only of CLT1, but also of AIB’s broader strategy.

Our thesis has been straightforward: in an AI economy increasingly constrained by access to power, securing scalable power infrastructure can create significant strategic value. We believe the Nebius agreement demonstrates our ability to convert that infrastructure into long-term contracted customer relationships.

We also completed a strategic acquisition in Texas, increasing AIB’s total contracted utility power capacity from 65 MW to approximately 120 MW. This acquisition expands our power portfolio and provides another site for pursuing AI and high-performance computing opportunities.

Funding CLT1

I want to directly address a question that is important to our shareholders: How does AIB intend to fund the development of CLT1?

Our current development plan combines substantial customer prepayments and project-level financing, including potential debt and preferred equity. As a result, we do not currently anticipate requiring corporate-level common equity to fund the development of CLT1.

We believe this distinction is important. As we execute our growth strategy, management remains highly focused on balancing growth with responsible capital allocation and protecting long-term shareholder value.

From Power to Contracted Capacity

The Nebius agreement represents more than a single customer contract. It demonstrates the ongoing progression of our business model:

Secure Power → Contract Customer Capacity → Secure Project Funding → Develop and Deliver Infrastructure → Generate Long-Term Revenue

We believe the scarcity of available power suitable for large-scale AI infrastructure creates an increasingly valuable opportunity for companies capable of securing that power and delivering data center capacity on timelines that meet customer requirements. Our objective is to repeat this model across the AIB portfolio.

Looking Ahead

Moving forward, our immediate priority is advancing CLT1 toward delivery, securing the project financing contemplated under our development plan, meeting our commitments to Nebius, and continuing to advance the broader AIB development portfolio.

We continue to evaluate opportunities to expand our portfolio of power-rich sites capable of supporting AI and high-performance computing infrastructure. AIB is a fundamentally stronger company than it was just 30 days ago. We have secured a major AI infrastructure customer and established commercial validation for our development strategy, strengthened our portfolio, and established a financing path for CLT1 that does not currently require corporate-level common equity.

The next phase is about execution, and that is exactly where our focus is today.

On behalf of the entire AIB team, thank you to our shareholders for your continued support, and we look forward to providing more updates on our progress in the future.

Jerry Tang
Chief Executive Officer
AIB Data Centers, Inc.

About AIB Data Centers

AIB Data Centers Inc. is a developer and operator of digital infrastructure focused on AI hosting and high-performance computing workloads. The Company’s platform combines access to reliable, scalable power resources with modular infrastructure deployment designed to accelerate the development of next-generation compute capacity.

We routinely post information that may be important to investors on the Company’s website. For more information on AIB Data Centers, please visit www.aib.us.

Safe Harbor / Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s participation in upcoming investor events, the development and delivery of contracted capacity, the expected sources and timing of customer prepayments and project funding, its contracted power portfolio, and its development pipeline, and growth and financing strategy, These statements are based on management’s current expectations and are subject to risks and uncertainties, including the availability of capital, customer demand, the timing and completion of utility construction and interconnection work, and other factors described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially.

Investor Relations Contact:
Chris Tyson, Executive Vice President
MZ Group – MZ North America
949-491-8235
AIB@mzgroup.us
www.mzgroup.us

BOCA RATON, FL, Oct. 07, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that Chief Executive Officer Joseph Onorati and Chief Strategy Officer Dan Kang will present at the 2026 Maxim Growth Summit, taking place October 12–14, 2026, at the Hard Rock Hotel in New York City.

The presentation will discuss the Company’s SOL treasury strategy and CHAD, its Nasdaq-listed variable-rate preferred stock, as a funding source for its next phase of growth. The Company will also participate in one-on-one meetings with institutional investors.

Portions of the event will be streamed online at digital.maximgrp.com. A recording of the Company’s presentation will be available for replay in the days following the event. For more information about the conference, please visit www.maximgrp.com/2026-growth-summit.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

Management to Review Third-Quarter Performance and Provide Updates on Ongoing Initiatives

PROVIDENCE, R.I., Oct. 07, 2026 (GLOBE NEWSWIRE) — via IBN — Beeline Holdings, Inc. (NASDAQ: BLNE), the fast-growing digital mortgage platform redefining the path to homeownership, today announced it will host a stakeholder update call on the results of the third quarter of 2026 on Thursday, Nov. 12, 2026, at 5 p.m. ET.

The call will be hosted by Nick Liuzza, Chief Executive Officer, and Chris Moe, Chief Financial Officer, who will review the company’s performance and provide updates on ongoing initiatives.

Call Details:

• Listen-only webcast:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=mxJpJirm

• Toll-Free Dial-In (U.S.): 877-317-6789
• International Dial-In: 412-317-6789

About Beeline

Beeline Holdings, Inc. is a technology-driven mortgage and home-finance company focused on simplifying and accelerating the path to homeownership, property investment and home-equity access. Through its digital platform, Beeline offers mortgage products designed for traditional borrowers, self-employed borrowers and real estate investors and is expanding its platform into home equity investment products. We believe everyone’s an investor seeking greater financial freedom. That’s why we’re leveling the playing field with the fastest, simplest loans and access to home-equity ever, helping you reach your financial happy place.

Contact:
ir@makeabeeline.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Nature Communications publication provides new evidence that Vaccinex’s pepinemab may help reshape the tumor environment to support a coordinated immune attack on cancer, potentially complementing checkpoint inhibitors and other immunotherapies

ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) — Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced the publication in Nature Communications of results from an Emory University and Winship Cancer Institute-sponsored pilot study evaluating pepinemab in patients with metastatic melanoma. The publication represents an important milestone in an almost decade-long scientific partnership between Vaccinex and Winship investigators, focused on advancing the understanding of SEMA4D biology and its potential application in cancer immunotherapy. The findings provide new evidence in human cancer supporting Vaccinex’s strategy of targeting SEMA4D to reshape the tumor immune environment and promote conditions that support recognition of cancer cells and a coordinated antitumor immune response that may complement checkpoint inhibitors and other immunotherapies.

The study evaluated pepinemab in combination with the checkpoint inhibitors nivolumab and/or ipilimumab before surgery in patients with resectable metastatic melanoma. Consistent with its biomarker-driven design, the study focused on measuring treatment-associated changes in tumor immunity. The predefined primary biomarker endpoint was met; the trial was not powered to establish clinical efficacy.

Researchers found that pepinemab-containing regimens were associated with broad changes in the tumor microenvironment consistent with enhanced antitumor immunity. These changes included stronger biomarker signals associated with tumor recognition and antigen presentation, recruitment and activation of immune cells, and the development of highly organized immune structures known as mature lymphoid aggregates.

Importantly, greater abundance of mature lymphoid aggregates was associated with longer recurrence-free survival. This observation provides an encouraging link between the immune remodeling identified in the study and patient outcomes; however, the small biomarker-focused trial was not designed to demonstrate a clinical benefit from pepinemab. Confirmation in larger, randomized studies will be needed.

The publication, “Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial,” is the result of a longstanding scientific collaboration between Vaccinex and investigators at Winship Cancer Institute of Emory University led by Michael C. Lowe, MD, MA, Gregory B. Lesinski, PhD, MPH, and Chrystal M. Paulos, PhD with additional contributions from The University of Texas MD Anderson Cancer Center led by Jennifer Wargo, MD, MMSc. The investigator-initiated trial was sponsored by Emory University and Winship Cancer Institute, with Vaccinex providing pepinemab together with scientific and research support. Vaccinex Research leaders included Elizabth Evans, PhD, Senior Vice President Discovery and Translational Medicine, and Crystal Mallow, Senior Research Scientist, who developed novel immunohistochemical methods for this study.

Key Findings

1. Pepinemab was associated with broad remodeling of the tumor immune environment. SEMA4D blockade was associated with changes across several components of antitumor immunity, including biological programs involved in antigen presentation, immune-cell recruitment and activation, together with changes in myeloid cells that can influence whether the tumor environment suppresses or supports an immune response.
2. Pepinemab-containing regimens were associated with highly organized immune structures within tumors. Mature lymphoid aggregates contained distinct populations of immune cells arranged in defined regions that enable local immune interactions. Some aggregates displayed features resembling tertiary lymphoid structures (TLS), specialized sites where multiple components of an immune response can come together within or near tumors.
3. More mature immune structures were associated with longer recurrence-free survival. Patients with greater abundance of mature lymphoid aggregates tended to remain recurrence-free longer. Additional analyses found evidence of expanded T- and B-cell populations within these structures, supporting the concept that they represented sites of active immune responses. Because the trial was designed to study biological effects and included a relatively small number of patients, these clinical associations are exploratory and require confirmation in larger studies.

About the Study

The investigator-sponsored pilot trial (NCT03769155) evaluated pepinemab in combination with nivolumab and/or ipilimumab in patients with resectable metastatic melanoma. Patients received two doses of treatment before planned surgery, allowing investigators to directly examine how the treatments affected the immune environment within subsequently resected tumors.

Thirty-eight patients participated in the study, and neoadjuvant treatment did not prevent or postpone curative-intent surgical resection. No grade 4 or 5 adverse events occurred during treatment before or after surgery.

The trial represents one component of a scientific partnership between Vaccinex and Winship Cancer Institute of Emory University, advancing SEMA4D research from mechanistic studies toward clinical evaluation in cancer. Vaccinex supplied pepinemab and supported multiple aspects of the research program, including scientific and operational oversight, generation and analysis of study data, and development of the scientific publication. Bristol Myers Squibb provided nivolumab and ipilimumab.

Together, these findings provide evidence from human tumors supporting the proposed mechanism of pepinemab and Vaccinex’s strategy of targeting SEMA4D as a means of reshaping the tumor immune environment. By promoting conditions associated with improved antigen presentation, immune-cell recruitment and organized adaptive immunity, SEMA4D blockade may offer a complementary approach to checkpoint inhibition and other cancer immunotherapies. The results support continued evaluation of pepinemab-containing combinations in melanoma and other solid tumors.

Publication

Ruffin, A.T., Mallow, C.L., Olson, B.M. et al. Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-78231-3

Clinical trial: NCT03769155

About Pepinemab

Pepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can otherwise bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton in cells and lead to loss of homeostatic functions of astrocytes and other glial cells in the brain and of dendritic cells in immune tissue. Pepinemab appears to be well-tolerated with a favorable safety profile in multiple clinical trials in different neurological and cancer indications.

About Vaccinex Inc.

Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brain and prevents infiltration and activation of immune cells in tumors. Pepinemab is being studied as a monotherapy in Alzheimer’s Disease, and the Company has previously published promising Phase 2 data in Huntington’s disease. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: clinicaltrials.gov. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about expectations and objectives with respect to the results and timing of the SIGNAL-AD clinical trials; our plans, expectations and objectives with respect to the results and timing of the SIGNAL-AD and KEYNOTE-B84 clinical trials; the use and potential benefits of pepinemab in R/M HNSCC, lung cancer, metastatic pancreatic adenocarcinoma (PDAC) and other indications; the potential for benefits as compared to single agent KEYTRUDA® or BAVENCIO®; expectations with respect to the collaboration of Merck,; and other statements identified by words such as “anticipate,” “believe,” “plans,” “schedule,” “being,” “will,” “appears,” “expect,” “ongoing,” “potential,” “promising,” “suggest”, and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports and the other risks and uncertainties described in the Company’s annual year-end filings.

Investor Contact

Elizabeth Evans, PhD
Chief Operating Officer, Vaccinex, Inc.
(585) 271-2700
eevans@vaccinex.com

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 OCTOBER 2026 AT 15.30 P.M. EET, MAJOR SHAREHOLDER ANNOUNCEMENT

Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of Kuortaneen Säästöpankkisäätiö in Oma Savings Bank Plc has fallen below the flagging threshold

On 7 October 2026, Oma Savings Bank Plc (OmaSp) received a notification under Chapter 9, Section 5 of the Securities Market Act (SMA) from Kuortaneen Säästöpankkisäätiö (business ID 0134703-0), according to which Kuortaneen Säästöpankkisäätiö’s holding and voting rights in OmaSp has fallen below the flagging threshold on 7 October 2026.

According to the announcement, Kuortaneen Säästöpankkisäätiö sr owns 0 OmaSp shares, corresponding to 0 percent of OmaSp’s shares and votes.

OmaSp has one class of shares in which each share has one vote. The total number of shares is 33,356,729.

The holding of Kuortaneen Säästöpankkisäätiö sr according to the announcement:

	% of shares and voting rights (A)	% of shares and voting rights through financial instruments (B)	Total of both in % (A+B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0	0	0	33,356,729
Positions of previous notification (if threshold crossed)	0		0

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares	Number of shares and voting rights		% of shares and voting rights
ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000306733	0	0	0	0
A total	0		0

Oma Savings Bank Plc

Additional information:

Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi

Distribution:

Nasdaq Helsinki Ltd
Major media
www.omasp.fi

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki. Oma Savings Bank is a part of S-Bank Group.

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 OCTOBER 2026 AT 15.30 P.M. EET, MAJOR SHAREHOLDER ANNOUNCEMENT

Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of Töysän Säästöpankkisäätiö in Oma Savings Bank Plc has fallen below the flagging threshold

On 7 October 2026, Oma Savings Bank Plc (OmaSp) received a notification under Chapter 9, Section 5 of the Securities Market Act (SMA) from Töysän Säästöpankkisäätiö (business ID 0134703-0), according to which Töysän Säästöpankkisäätiö’s holding and voting rights in OmaSp has fallen below the flagging threshold on 7 October 2026.

According to the announcement, Töysän Säästöpankkisäätiö sr owns 0 OmaSp shares, corresponding to 0 percent of OmaSp’s shares and votes.

OmaSp has one class of shares in which each share has one vote. The total number of shares is 33,356,729.

The holding of Töysän Säästöpankkisäätiö sr according to the announcement:

	% of shares and voting rights (A)	% of shares and voting rights through financial instruments (B)	Total of both in % (A+B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0		0	33,356,729
Positions of previous notification (if threshold crossed)	9,85		9,85

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares	Number of shares and voting rights		% of shares and voting rights
ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000306733	0	0	0	0
A total	0		0

Oma Savings Bank Plc

Additional information:

Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi

Distribution:

Nasdaq Helsinki Ltd
Major media
www.omasp.fi

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki. Oma Savings Bank is a part of S-Bank Group.

Brings 15 years of pharma launch, health system, and direct-to-patient engagement experience as Achieve prepares for potential commercialization of cytisinicline

SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve’s executive team and will lead its marketing, brand strategy, and corporate communications as the Company prepares for the potential commercialization of cytisinicline.

Tuson has spent 15 years building, launching, and scaling brands across the healthcare industry, with go-to-market leadership spanning dozens of launches, six of them in pharma, including three blockbuster therapies. She specializes in designing high-engagement, direct-to-patient experiences and has led campaigns, both for healthcare providers and consumers, from strategy through execution across more than 40 therapeutic areas and conditions globally.

“We are delighted to welcome Kait to Achieve at this important time. Her experience across brand building, product launch strategy, patient engagement, and health systems will be invaluable as we advance toward our planned NDA resubmission and prepare for the potential commercialization of cytisinicline,” said Andrew D. Goldberg, MD, Chief Executive Officer, Achieve. “Kait will lead our efforts to build understanding of nicotine dependence as a treatable condition among patients, healthcare professionals, and other key stakeholders.”

“Smoking remains the leading cause of preventable death in the world, and the tools available to help people quit haven’t meaningfully changed in two decades,” said Tuson. “I’ve spent my career building healthcare brands that turn science into something patients can act on, meeting them where they are and earning the trust of the clinicians who guide them. I’m honored to bring that experience to Achieve at a moment when cytisinicline has the potential to change what’s possible for millions of people who want and need to quit smoking and vaping.”

Tuson’s appointment builds on a series of steps Achieve has made in 2026 to prepare for potential commercialization, including the appointment of Andrew D. Goldberg, MD as Chief Executive Officer, a financing of up to $354 million, and the additions of senior commercial, manufacturing, and quality leadership.

ABOUT ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

ABOUT CYTISINICLINE
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.²^,³

In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.¹ In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.⁴ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the timing and outcome of Achieve’s planned NDA resubmission for cytisinicline, the timing of any FDA decision, the potential benefits of cytisinicline, the potential market for cytisinicline, the Company’s commercialization plans and readiness, and the anticipated benefits of new executive leadership. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. These statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACT
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510

REFERENCES
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
⁴Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, Nicotine & Tobacco Research, 2026; ntag116, doi.org/10.1093/ntr/ntag116.

Eliminated More Than $14.9 Million of Debt, Further Strengthening Capital Structure and Liquidity

WEST PALM BEACH, FL, Oct. 07, 2026 (GLOBE NEWSWIRE) — AVAX One Technology Ltd. (NASDAQ: AVX) (“AVAX One” or the “Company”), today announced significant progress on strengthening its balance sheet during the third quarter of 2026, including a material reduction in near-term convertible debt and continued share repurchases during the quarter of 333,500 (as adjusted to reflect the Company’s one-for-twelve reverse stock split effected on June 15, 2026).

During the third quarter of 2026, approximately $7.1 million of convertible debentures were converted into common shares, approximately $7.4 million of debt was repaid by the Company and $0.4 million of debt was redeemed into common shares. As a result of these conversions, AVAX One has reduced its convertible debt balance to approximately $970,000 as of September 30, 2026, strengthening its balance sheet and enhancing financial flexibility and liquidity.

“Q3 marked another period of strong progress for AVAX One, highlighted by a significant reduction in our outstanding convertible debt and continued execution under our share repurchase program,” said Pete Wylie, Interim Chief Executive Officer and Chief Operating Officer of AVAX One. “Over the past several months, we have simplified our balance sheet, preserved financial flexibility and allocated capital where we believe it can generate the greatest value for shareholders. With a stronger financial foundation in place, we believe we are well positioned to execute on our growth and profitability initiatives as we enter the next phase of our digital asset treasury strategy.”

As of September 30, 2026, AVAX One had approximately 9,987,248 million common shares outstanding, compared with approximately 7,363,270 million as of June 30, 2026.

About AVAX One Technology Ltd.

AVAX One Technology Ltd. (NASDAQ: AVX) is a digital infrastructure company accelerating the transition to an onchain financial economy. The Company maintains a strategic Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation. It also operates bitcoin mining facilities and develops modular data centers. These three pillars give public market investors unique exposure to both the onchain economy and the digital infrastructure layer. For more information, please visit www.avax-one.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of words such as “anticipate,” “expect,” “intend,” “plan,” “could,” “may,” “will,” “would,” “believe,” “estimate,” “target,” “project,” and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: risks relating to the Company’s operations and business, including the highly volatile nature of the price of Bitcoin, AVAX, and other digital assets, and the risk that the price of the Company’s securities may be highly correlated to the price of the digital assets it holds; plans to repurchase the Company’s common shares and the timing and amount of any such repurchases; increased competition in the data center, AI/HPC, and digital asset industries; and legal, commercial, regulatory, and technical uncertainties affecting the Company’s business, as well as those risks and uncertainties identified in the Company’s filings with the U.S. Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future events, or otherwise.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
AVX@elevate-ir.com

Media Contact
Ethan Lyle
Prospero
avax-one@prospero.agency

New York, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced its participation in recent and upcoming investor conferences.

• Inaugural ROTH Emerging Nuclear Technology Conference on October 1^st in New York, NY.
• TD Cowen’s 11th Annual Nuclear Roundtable on October 8^th, held virtually.
  • Management will participate in a fireside chat at 2:50 p.m. ET, with the webcast link and a replay available for approximately 30 days on NANO Nuclear’s investor relations website at https://ir.nanonuclearenergy.com/news-events/events.
• 3^rd Annual Daiwa Miami Conference on November 19^th, in Miami, FL.

To request an invitation or to schedule a one-on-one meeting with management at one of the conferences above, please contact your respective investment bank representatives.

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR^™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS^™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR^™ system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR^™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:

Email: IR@NANONuclearEnergy.com
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:

NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This press release and presentations and discussions at the investor conferences described herein, and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “plans”, “aim,” “goal,” “believes”, “potential”, “future,” “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with conditions to closing the asset purchase agreement, which may not be satisfied, including for reasons beyond NANO Nuclear’s control, as well as the following: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the U.S. Department of Energy, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).

“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability,” said Howard Horn, chief financial officer and executive vice president, corporate strategy. “GENGLYCOS itself benefited from capital generated from a previous PRV sale, demonstrating the important role the PRV program plays in helping companies develop transformative therapies for rare disease patients.”

The closing of the PRV transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

Jefferies LLC is serving as exclusive financial advisor and Gibson, Dunn and Crutcher LLP is serving as legal counsel to Ultragenyx on this transaction.

About the Rare Pediatric Disease Priority Review Voucher Program
This U.S. FDA program is intended to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Under this program, a sponsor who receives an approval for a drug or biologic for a “rare pediatric disease” may qualify for a PRV that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor receives the PRV upon approval of the rare pediatric disease product application, and it can be sold or transferred.

About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at: www.ultragenyx.com.

Forward-Looking Statements and Use of Digital Media
Except for the historical information contained herein, the matters set forth in this press release, including statements relating to Ultragenyx’s expectations regarding the consummation and timing of the PRV transaction, the amount and receipt of the cash consideration, and the anticipated use and benefits of the proceeds, including advancing Ultragenyx’s pipeline and supporting its path to profitability, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve substantial risks and uncertainties that could cause Ultragenyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties relating to the satisfaction of the closing conditions for the PRV transaction, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the possibility that the transaction may be delayed or may not close, Ultragenyx’s ability to realize the anticipated benefits of the transaction and use the proceeds as anticipated, the sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the uncertainties inherent in clinical drug development and the regulatory approval process, risks related to serious or undesirable side effects of Ultragenyx’s products and product candidates, manufacturing risks, market acceptance, uncertainty related to insurance coverage and reimbursement, and the availability or commercial potential of Ultragenyx’s products and product candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2026, and its subsequent periodic reports filed with the SEC.

In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).

Ultragenyx Contacts

Investors
Joshua Higa
ir@ultragenyx.com

Media
Jess Rowlands
media@ultragenyx.com